Diagnosis of Histoplasmosis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Congo DRC, Kamwiziku. Mycoses 2021
Received: 8 April 2021 | Revised: 1 June 2021 | Accepted: 10 June 2021 DOI: 10.1111/myc.13339 REVIEW ARTICLE Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates Guyguy K. Kamwiziku1 | Jean- Claude C. Makangara1 | Emma Orefuwa2 | David W. Denning2,3 1Department of Microbiology, Kinshasa University Hospital, University of Abstract Kinshasa, Kinshasa, Democratic Republic A literature review was conducted to assess the burden of serious fungal infections of Congo 2Global Action Fund for Fungal Infections, in the Democratic Republic of the Congo (DRC) (population 95,326,000). English and Geneva, Switzerland French publications were listed and analysed using PubMed/Medline, Google Scholar 3 Manchester Fungal Infection Group, The and the African Journals database. Publication dates spanning 1943– 2020 were in- University of Manchester, Manchester Academic Health Science Centre, cluded in the scope of the review. From the analysis of published articles, we estimate Manchester, UK a total of about 5,177,000 people (5.4%) suffer from serious fungal infections in the Correspondence DRC annually. The incidence of cryptococcal meningitis, Pneumocystis jirovecii pneu- Guyguy K. Kamwiziku, Department monia in adults and invasive aspergillosis in AIDS patients was estimated at 6168, of Microbiology, Kinshasa University Hospital, University of Kinshasa, Congo. 2800 and 380 cases per year. Oral and oesophageal candidiasis represent 50,470 Email: [email protected] and 28,800 HIV- infected patients respectively. Chronic pulmonary aspergillosis post- tuberculosis incidence and prevalence was estimated to be 54,700. Fungal asthma (allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitiza- tion) probably has a prevalence of 88,800 and 117,200. -
Estimated Burden of Serious Fungal Infections in Ghana
Journal of Fungi Article Estimated Burden of Serious Fungal Infections in Ghana Bright K. Ocansey 1, George A. Pesewu 2,*, Francis S. Codjoe 2, Samuel Osei-Djarbeng 3, Patrick K. Feglo 4 and David W. Denning 5 1 Laboratory Unit, New Hope Specialist Hospital, Aflao 00233, Ghana; [email protected] 2 Department of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana, P.O. Box KB-143, Korle-Bu, Accra 00233, Ghana; [email protected] 3 Department of Pharmaceutical Sciences, Faculty of Health Sciences, Kumasi Technical University, P.O. Box 854, Kumasi 00233, Ghana; [email protected] 4 Department of Clinical Microbiology, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi 00233, Ghana; [email protected] 5 National Aspergillosis Centre, Wythenshawe Hospital and the University of Manchester, Manchester M23 9LT, UK; [email protected] * Correspondence: [email protected] or [email protected] or [email protected]; Tel.: +233-277-301-300; Fax: +233-240-190-737 Received: 5 March 2019; Accepted: 14 April 2019; Published: 11 May 2019 Abstract: Fungal infections are increasingly becoming common and yet often neglected in developing countries. Information on the burden of these infections is important for improved patient outcomes. The burden of serious fungal infections in Ghana is unknown. We aimed to estimate this burden. Using local, regional, or global data and estimates of population and at-risk groups, deterministic modelling was employed to estimate national incidence or prevalence. Our study revealed that about 4% of Ghanaians suffer from serious fungal infections yearly, with over 35,000 affected by life-threatening invasive fungal infections. -
Therapeutic Class Overview Onychomycosis Agents
Therapeutic Class Overview Onychomycosis Agents Therapeutic Class • Overview/Summary: This review will focus on the antifungal agents Food and Drug Administration (FDA)-approved for the treatment of onychomycosis.1-9 Onychomycosis is a progressive infection of the nail bed which may extend into the matrix or plate, leading to destruction, deformity, thickening and discoloration. Of note, these agents are only indicated when specific types of fungus have caused the infection, and are listed in Table 1. Additionally, ciclopirox is only FDA-approved for mild to moderate onychomycosis without lunula involvement.1 The mechanisms by which these agents exhibit their antifungal effects are varied. For ciclopirox (Penlac®) the exact mechanism is unknown. It is believed to block fungal transmembrane transport, causing intracellular depletion of essential substrates and/or ions and to interfere with ribonucleic acid (RNA) and deoxyribonucleic acid (DNA).1 The azole antifungals, efinaconazole (Jublia®) and itraconazole tablets (Onmel®) and capsules (Sporanox®) works via inhibition of fungal lanosterol 14-alpha-demethylase, an enzyme necessary for the biosynthesis of ergosterol. By decreasing ergosterol concentrations, the fungal cell membrane permeability is increased, which results in leakage of cellular contents.2,5,6 Griseofulvin microsize (Grifulvin V®) and ultramicrosize (GRIS-PEG®) disrupts the mitotic spindle, arresting metaphase of cell division. Griseofulvin may also produce defective DNA that is unable to replicate. The ultramicrosize tablets are absorbed from the gastrointestinal tract at approximately one and one-half times that of microsize griseofulvin, which allows for a lower dose of griseofulvin to be administered.3,4 Tavaborole (Kerydin®), is an oxaborole antifungal that interferes with protein biosynthesis by inhibiting leucyl-transfer ribonucleic acid (tRNA) synthase (LeuRS), which prevents translation of tRNA by LeuRS.7 The final agent used for the treatment of onychomycosis, terbinafine hydrochloride (Lamisil®), is an allylamine antifungal. -
Fungal Endophthalmitis
............................ Mycosis of the Eye and Its Adnexa .. ............................ Developments in Ophthalmology Vol. 32 Series Editor W. Behrens-Baumann, Magdeburg ............................ Mycosis of the Eye and Its Adnexa W. Behrens-Baumann, Magdeburg with a contribution by R. RuÈchel,GoÈttingen 39 ®gures, 31 in color, and 39 tables, 1999 ............................ Prof. Dr. med. W. Behrens-Baumann Klinik fuÈr Augenheilkunde, Otto-von-Guericke-UniversitaÈt Leipziger Strasse 44, D±39120 Magdeburg This is a revised and extended translation of a former German version entitled Pilzerkrankungen des Auges by Wolfgang Behrens-Baumann The reproduction of the color illustrations in this book was made possible by a generous contribution from the Heinz Karger Memorial Foundation Continuation of `Bibliotheca Ophthalmologica', `Advances in Ophthalmology', and `Modern Problems in Ophthalmology' Founded 1926 as `Abhandlungen aus der Augenheilkunde und ihren Grenzgebieten' by C. Behr, Hamburg and J. Meller, Wien Former Editors: A. BruÈckner, Basel (1938±1959); H. J. M. Wewe, Utrecht (1938±1962); H. M. Dekking, Groningen (1954±1966); E. R. StreiV, Lausanne (1954±1979); J. FrancËois, Gand (1959±1979); J. van Doesschate, Utrecht (1967±1971); M. J. Roper-Hall, Birmingham (1966±1980); H. Sautter, Hamburg (1966±1980); W. Straub, Marburg a. d. Lahn (1981±1993) Library of Congress Cataloging-in-Publication Data Behrens-Baumann, Wolfgang. [Pilzerkrankungen des Auges, English] Mycosis of the eye and its adnexa / W. Behrens-Baumann; with a contribution by R. Ruchel. (Developments in ophthalmology; vol. 32) Includes bibliographical references and indexes. 1. Oculomycoses. I. Ruchel, R. II. Title. III. Series. [DNLM: 1. Eye Infections, Fungal ± drug therapy. 2. Eye Infections, Fungal ± diagnosis. W1 DE998NG v.32 1999] RE901.F8B4413 1999 617.7 ± dc21 ISSN 0250±3751 ISBN 3±8055±6915±7 (hardcover : alk. -
Pulmonary Aspergillosis: What CT Can Offer Before Radiology Section It Is Too Late!
DOI: 10.7860/JCDR/2016/17141.7684 Review Article Pulmonary Aspergillosis: What CT can Offer Before Radiology Section it is too Late! AKHILA PRASAD1, KSHITIJ AGARWAL2, DESH DEEPAK3, SWAPNDEEP SINGH ATWAL4 ABSTRACT Aspergillus is a large genus of saprophytic fungi which are present everywhere in the environment. However, in persons with underlying weakened immune response this innocent bystander can cause fatal illness if timely diagnosis and management is not done. Chest infection is the most common infection caused by Aspergillus in human beings. Radiological investigations particularly Computed Tomography (CT) provides the easiest, rapid and decision making information where tissue diagnosis and culture may be difficult and time-consuming. This article explores the crucial role of CT and offers a bird’s eye view of all the radiological patterns encountered in pulmonary aspergillosis viewed in the context of the immune derangement associated with it. Keywords: Air-crescent, Fungal ball, Halo sign, Invasive aspergillosis INTRODUCTION diagnostic pitfalls one encounters and also addresses the crucial The genus Aspergillus comprises of hundreds of fungal species issue as to when to order for the CT. ubiquitously present in nature; predominantly in the soil and The spectrum of disease that results from the Aspergilla becoming decaying vegetation. Nearly, 60 species of Aspergillus are a resident in the lung is known as ‘Pulmonary Aspergillosis’. An medically significant, owing to their ability to cause infections inert colonization of pulmonary cavities like in cases of tuberculosis in human beings affecting multiple organ systems, chiefly the and Sarcoidosis, where cavity formation is quite common, makes lungs, paranasal sinuses, central nervous system, ears and skin. -
PRIOR AUTHORIZATION CRITERIA BRAND NAME (Generic) SPORANOX ORAL CAPSULES (Itraconazole)
PRIOR AUTHORIZATION CRITERIA BRAND NAME (generic) SPORANOX ORAL CAPSULES (itraconazole) Status: CVS Caremark Criteria Type: Initial Prior Authorization Policy FDA-APPROVED INDICATIONS Sporanox (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Sporanox Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. Compendial Uses Coccidioidomycosis2,3 -
70-2294 ALY, Raza, 1935- IMMÜNOLOGICAL RESPONSE OF
This dissertation has been microfilmed exactly as received 70-2294 ALY, Raza, 1935- IMMÜNOLOGICAL RESPONSE OF GUINEA PIGS CHRONICALLY INFECTED WITH REPEATED AND A SINGLE DOSE OF HISTOPLASMA DUBOISII. The University of Oklahoma, Ph.D., 1969 Microbiology University Microfilms, Inc., Ann Arbor, Michigan THE UNIVERSITY OF OKLAHOMA GRADUATE COLLEGE IMMUNOLOGICAL RESPONSE OF GUINEA PIGS CHRONICALLY INFECTED WITH REPEATED AND A SINGLE DOSE OF HISTOPLASMA DUBOISII A DISSERTATION SUBMITTED TO THE GRADUATE FACULTY in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY BY RAZA ALY Norman, Oklahoma 1969 IMMUNOLOGICAL RESPONSE OF GUINEA PIGS CHRONICALLY INFECTED WITH REPEATED AND A SINGLE DOSE OF HISTOPLASMA DUBOISII APPROVED BY DISSERTATION COMMITTEE ACKNOWLEDGEMENT The author wishes to express his sincere thanks to Dr. Howard W. Larsh for his inspiration and continued guidance throughout this study. A special note of thanks to Dr. G. C. Cozad, Dr. J. H, Lancaster I Dr. D. 0. Cox, and Dr. L. S. Ciereszko for their assistance in the writing of this manuscript. Sincere appréciation to Dr. Peter A. Bartels for his assis tance. A special note of appreciation is also extended to Miss Janis Reeser, Miss Mary Jane Hook, and Mr. Don Wiggins for their technical assistance in this study. Also, a special note of appreciation to my wife Naheed for editing and typing the manuscript. Ill TABLE OF CONTENTS Page LIST OF TABLES ............... » . v LIST OF ILLUSTRATIONS . .............. vi Chapter I. INTRODUCTION .......... ............ 1 II. MATERIALS AND METHODS ........... .. 8 III. RESULTS ............. 22 IV. DISCUSSION ........... 42 V. SUMMARY AND CONCLUSIONS........... 48 BIBLIOGRAPHY ............. 5© IV LIST OF TABLES Table Page 1. -
Acute Disseminated Histoplasmosis of Pulmonary Origin Probably Contracted in Britain by A
Thorax: first published as 10.1136/thx.16.4.388 on 1 December 1961. Downloaded from Thorax (1961), 16, 388. ACUTE DISSEMINATED HISTOPLASMOSIS OF PULMONARY ORIGIN PROBABLY CONTRACTED IN BRITAIN BY A. A. MILLER, F. RAMSDEN, AND M. R. GEAKE From the Group Laboratory, Preston Royal Infirmary, and Sharoe Green Hospital, Preston (RECEIVED FOR PUBLICATION NOVEMBER 28, 1960) Histoplasmosis in any form is an unusual made a comprehensive study of the varied radio- finding in Great Britain. The case described in logical appearances in 28 cases of histoplasmosis; this paper is that of a man with bilateral of these cases nine showed pulmonary involve- pulmonary histoplasmosis which terminated with ment. Furcolow (1960) indicates that at least 30% an acute disseminated infection. It is believed to of positive skin test reactors have, or develop, be an example of an indigenous British infection. demonstrable lesions. Symmers (1956) made a critical analysis of the 15 cases of histoplasmosis reported in Great INDIGENOUS INFECTIONS Britain up to 1956 and found two of them The first unequivocal, mycologically proved (Limerick, 1951) unacceptable as there was instance of histoplasmosis in which the infection insufficient evidence to warrant the diagnosis of was contracted in Britain is believed to be that copyright. histoplasmosis. Earle, Highman, and Lockley reported by Symmers (1956) and was a case of (1960) described a fatal case of acute disseminated histoplasmic lymphadenitis. histoplasmosis in a man aged 62 years who had In the case described here the patient had never lived in India for 30 years and contracted the been outside Great Britain except during the disease in that country. -
Detection of Histoplasma DNA from Tissue Blocks by a Specific
Journal of Fungi Article Detection of Histoplasma DNA from Tissue Blocks by a Specific and a Broad-Range Real-Time PCR: Tools to Elucidate the Epidemiology of Histoplasmosis Dunja Wilmes 1,*, Ilka McCormick-Smith 1, Charlotte Lempp 2 , Ursula Mayer 2 , Arik Bernard Schulze 3 , Dirk Theegarten 4, Sylvia Hartmann 5 and Volker Rickerts 1 1 Reference Laboratory for Cryptococcosis and Uncommon Invasive Fungal Infections, Division for Mycotic and Parasitic Agents and Mycobacteria, Robert Koch Institute, 13353 Berlin, Germany; [email protected] (I.M.-S.); [email protected] (V.R.) 2 Vet Med Labor GmbH, Division of IDEXX Laboratories, 71636 Ludwigsburg, Germany; [email protected] (C.L.); [email protected] (U.M.) 3 Department of Medicine A, Hematology, Oncology and Pulmonary Medicine, University Hospital Muenster, 48149 Muenster, Germany; [email protected] 4 Institute of Pathology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany; [email protected] 5 Senckenberg Institute for Pathology, Johann Wolfgang Goethe University Frankfurt, 60323 Frankfurt am Main, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-30-187-542-862 Received: 10 November 2020; Accepted: 25 November 2020; Published: 27 November 2020 Abstract: Lack of sensitive diagnostic tests impairs the understanding of the epidemiology of histoplasmosis, a disease whose burden is estimated to be largely underrated. Broad-range PCRs have been applied to identify fungal agents from pathology blocks, but sensitivity is variable. In this study, we compared the results of a specific Histoplasma qPCR (H. qPCR) with the results of a broad-range qPCR (28S qPCR) on formalin-fixed, paraffin-embedded (FFPE) tissue specimens from patients with proven fungal infections (n = 67), histologically suggestive of histoplasmosis (n = 36) and other mycoses (n = 31). -
Application to Add Itraconazole and Voriconazole to the Essential List of Medicines for Treatment of Fungal Diseases – Support Document
Application to add itraconazole and voriconazole to the essential list of medicines for treatment of fungal diseases – Support document 1 | Page Contents Page number Summary 3 Centre details supporting the application 3 Information supporting the public health relevance and review of 4 benefits References 7 2 | Page 1. Summary statement of the proposal for inclusion, change or deletion As a growing trend of invasive fungal infections has been noticed worldwide, available few antifungal drugs requires to be used optimally. Invasive aspergillosis, systemic candidiasis, chronic pulmonary aspergillosis, fungal rhinosinusitis, allergic bronchopulmonary aspergillosis, phaeohyphomycosis, histoplasmosis, sporotrichosis, chromoblastomycosis, and relapsed cases of dermatophytosis are few important concern of southeast Asian regional area. Considering the high burden of fungal diseases in Asian countries and its associated high morbidity and mortality (often exceeding 50%), we support the application of including major antifungal drugs against filamentous fungi, itraconazole and voriconazole in the list of WHO Essential Medicines (both available in oral formulation). The inclusion of these oral effective antifungal drugs in the essential list of medicines (EML) would help in increased availability of these agents in this part of the world and better prompt management of patients thereby reducing mortality. The widespread availability of these drugs would also stimulate more research to facilitate the development of better combination therapies. -
Estimation of the Burden of Serious Human Fungal Infections in Malaysia
Journal of Fungi Article Estimation of the Burden of Serious Human Fungal Infections in Malaysia Rukumani Devi Velayuthan 1,*, Chandramathi Samudi 1, Harvinder Kaur Lakhbeer Singh 1, Kee Peng Ng 1, Esaki M. Shankar 2,3 ID and David W. Denning 4,5 ID 1 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; [email protected] (C.S.); [email protected] (H.K.L.S.); [email protected] (K.P.N.) 2 Centre of Excellence for Research in AIDS (CERiA), Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; [email protected] 3 Department of Microbiology, School of Basic & Applied Sciences, Central University of Tamil Nadu (CUTN), Thiruvarur 610 101, Tamil Nadu, India 4 Faculty of Biology, Medicine and Health, The University of Manchester and Manchester Academic Health Science Centre, Oxford Road, Manchester M13 9PL, UK; [email protected] 5 The National Aspergillosis Centre, Education and Research Centre, Wythenshawe Hospital, Manchester M23 9LT, UK * Correspondence: [email protected]; Tel.: +60-379-492-755 Received: 11 December 2017; Accepted: 14 February 2018; Published: 19 March 2018 Abstract: Fungal infections (mycoses) are likely to occur more frequently as ever-increasingly sophisticated healthcare systems create greater risk factors. There is a paucity of systematic data on the incidence and prevalence of human fungal infections in Malaysia. We conducted a comprehensive study to estimate the burden of serious fungal infections in Malaysia. Our study showed that recurrent vaginal candidiasis (>4 episodes/year) was the most common of all cases with a diagnosis of candidiasis (n = 501,138). -
Monograph on Dimorphic Fungi
Monograph on Dimorphic Fungi A guide for classification, isolation and identification of dimorphic fungi, diseases caused by them, diagnosis and treatment By Mohamed Refai and Heidy Abo El-Yazid Department of Microbiology, Faculty of Veterinary Medicine, Cairo University 2014 1 Preface When I see the analytics made by academia.edu for the visitors to my publication has reached 244 in 46 countries in one month only, this encouraged me to continue writing documents for the benefit of scientists and students in the 5 continents. In the last year I uploaded 3 monographs, namely 1. Monograph on yeasts, Refai, M, Abou-Elyazeed, H. and El-Hariri, M. 2. Monograph on dermatophytes, Refai, M, Abou-Elyazeed, H. and El-Hariri, M. 3. Monograph on mycotoxigenic fungi and mycotoxins, Refai, M. and Hassan, A. Today I am uploading the the 4th documents in the series of monographs Monograph on dimorphic fungi, Refai, M. and Abou-Elyazeed, H. Prof. Dr. Mohamed Refai, 2.3.2014 Country 30 day views Egypt 51 2 Country 30 day views Ethiopia 22 the United States 21 Saudi Arabia 19 Iraq 19 Sudan 14 Uganda 12 India 11 Nigeria 9 Kuwait 8 the Islamic Republic of Iran 7 Brazil 7 Germany 6 Uruguay 4 the United Republic of Tanzania 4 ? 4 Libya 4 Jordan 4 Pakistan 3 the United Kingdom 3 Algeria 3 the United Arab Emirates 3 South Africa 2 Turkey 2 3 Country 30 day views the Philippines 2 the Netherlands 2 Sri Lanka 2 Lebanon 2 Trinidad and Tobago 1 Thailand 1 Sweden 1 Poland 1 Peru 1 Malaysia 1 Myanmar 1 Morocco 1 Lithuania 1 Jamaica 1 Italy 1 Hong Kong 1 Finland 1 China 1 Canada 1 Botswana 1 Belgium 1 Australia 1 Argentina 4 1.